US biopharma company Meilleur Technologies has entered a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4) to investigate the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in positron emission tomography (PET) scans.
The partnership will assess and determine the presence and extent of amyloid plaque accumulation in the brain, a hallmark of several neurodegenerative diseases such as Alzheimer’s disease (AD).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In April of this year, Navidea Biopharmaceuticals signed an asset purchase agreement that allows Meilleur to acquire certain assets and responsibilities related to the development and commercialisation of NAV-4694.
The agreement granted Meilleur an exclusive licence to develop and commercialise NAV-4694 anywhere in the world.
Recent advancements in diagnostic tools, including blood-based biomarker tests and AI-powered analysis have transformed early detection capabilities in AD.
Dementia cases are forecast to almost triple by 2050, meaning there is a large market for diagnostic, treatment, and preventative care devices. As of September 18, 2023, there are currently 76 active AD IVD devices in the pipeline and ten devices undergoing clinical trials, according to GlobalData.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLast month, Mitsubishi Electrical joined Okayama University and Osaka University on a collaborative project to build a magnetic particle imaging device to assess the likelihood of AD developing.
The device uses magnetic particles that bind to amyloid-β to image the accumulation and distribution of amyloid-β in the brain, potentially detecting AD before a patient develops symptoms.
